C-Cbl Reverses HER2-mediated Tamoxifen Resistance in Human Breast Cancer Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 May 4

PMID 29720121

Citations 9

Authors

Wei Li

Ling Xu

Xiaofang Che

Haizhou Li

Ye Zhang

Na Song

Ti Wen

Kezuo Hou

Yi Yang

Lu Zhou

Xing Xin

Lu Xu

Xue Zeng

Sha Shi

Yunpeng Liu

Xiujuan Qu

Yuee Teng

Affiliations

Soon will be listed here.

Abstract

Background: Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance.

Methods: MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth.

Results: MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression.

Conclusions: Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.

Citing Articles

c-CBL/LCK/c-JUN/ETS1/CD28 axis restrains childhood asthma by suppressing Th2 differentiation.

Yang N, Wang T Mol Med. 2024; 30(1):164.

PMID: 39342146 PMC: 11439220. DOI: 10.1186/s10020-024-00872-1.

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies.

Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H Front Pharmacol. 2024; 15:1432545.

PMID: 39130630 PMC: 11310040. DOI: 10.3389/fphar.2024.1432545.

Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2.

Yuan Y, Hao L, Huang J, Zhao F, Ju Y, Wang J Cell Death Dis. 2024; 15(6):460.

PMID: 38942760 PMC: 11213963. DOI: 10.1038/s41419-024-06853-w.

GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.

Marks B, Pipia I, Mukai C, Horibata S, Rice E, Danko C BMC Cancer. 2023; 23(1):138.

PMID: 36765275 PMC: 9912664. DOI: 10.1186/s12885-023-10559-1.

A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells.

Maadi H, Wang Z Cells. 2022; 11(24).

PMID: 36552857 PMC: 9777316. DOI: 10.3390/cells11244093.

References

Marin R, Ramirez C, Morales A, Gonzalez M, Alonso R, Diaz M . Modulation of Abeta-induced neurotoxicity by estrogen receptor alpha and other associated proteins in lipid rafts. Steroids. 2008; 73(9-10):992-6. DOI: 10.1016/j.steroids.2007.12.007. View

Khadka N, Cheng X, Ho C, Katsaras J, Pan J . Interactions of the anticancer drug tamoxifen with lipid membranes. Biophys J. 2015; 108(10):2492-2501. PMC: 4457044. DOI: 10.1016/j.bpj.2015.04.010. View

Milosevic J, Klinge J, Borg A, Foukakis T, Bergh J, Tobin N . Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer. 2013; 13:473. PMC: 3852062. DOI: 10.1186/1471-2407-13-473. View

Qu X, Sada K, Kyo S, Maeno K, Miah S, Yamamura H . Negative regulation of FcepsilonRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b. Blood. 2003; 103(5):1779-86. DOI: 10.1182/blood-2003-07-2260. View

Rangel N, Villegas V, Rondon-Lagos M . Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Breast Cancer (Dove Med Press). 2017; 9:537-550. PMC: 5614746. DOI: 10.2147/BCTT.S146247. View

Marquez D, Chen H, Curran E, Welshons W, Pietras R . Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Mol Cell Endocrinol. 2006; 246(1-2):91-100. DOI: 10.1016/j.mce.2005.11.020. View

Liu T, Nath K, Liu W, Zhou R, Chen I . A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts. NMR Biomed. 2015; 28(9):1087-96. PMC: 4537822. DOI: 10.1002/nbm.3342. View

Varshney P, Yadav V, Saini N . Lipid rafts in immune signalling: current progress and future perspective. Immunology. 2016; 149(1):13-24. PMC: 4981613. DOI: 10.1111/imm.12617. View

Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland J . ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol. 2012; 26(9):1567-77. PMC: 3434528. DOI: 10.1210/me.2012-1140. View

10.

Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M . Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen. Clin Breast Cancer. 2013; 13(4):247-53. DOI: 10.1016/j.clbc.2013.02.005. View

11.

Qu X, Miah S, Hatani T, Okazaki M, Hori-Tamura N, Yamamura H . Selective inhibition of Fcepsilon RI-mediated mast cell activation by a truncated variant of Cbl-b related to the rat model of type 1 diabetes mellitus. J Biochem. 2005; 137(6):711-20. DOI: 10.1093/jb/mvi088. View

12.

Acconcia F, Kumar R . Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 2005; 238(1):1-14. DOI: 10.1016/j.canlet.2005.06.018. View

13.

Li H, Xu L, Li C, Zhao L, Ma Y, Zheng H . Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells. Mol Cancer. 2014; 13:136. PMC: 4052283. DOI: 10.1186/1476-4598-13-136. View

14.

Nahta R, ORegan R . Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat. 2012; 135(1):39-48. DOI: 10.1007/s10549-012-2067-8. View

15.

Xu L, Qu X, Hu X, Zhu Z, Li C, Li E . Lipid raft-regulated IGF-1R activation antagonizes TRAIL-induced apoptosis in gastric cancer cells. FEBS Lett. 2013; 587(23):3815-23. DOI: 10.1016/j.febslet.2013.10.007. View

16.

Chakraborty S, ValiyaVeettil M, Sadagopan S, Paudel N, Chandran B . c-Cbl-mediated selective virus-receptor translocations into lipid rafts regulate productive Kaposi's sarcoma-associated herpesvirus infection in endothelial cells. J Virol. 2011; 85(23):12410-30. PMC: 3209366. DOI: 10.1128/JVI.05953-11. View

17.

Yoshimaru T, Komatsu M, Miyoshi Y, Honda J, Sasa M, Katagiri T . Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Sci. 2015; 106(5):550-8. PMC: 4452155. DOI: 10.1111/cas.12654. View

18.

Liu Z, Song Y, Wan L, Zhang Y, Zhou L . Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy. Life Sci. 2016; 149:104-13. DOI: 10.1016/j.lfs.2016.02.059. View

19.

Yang Z, Barnes C, Kumar R . Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res. 2004; 10(11):3621-8. DOI: 10.1158/1078-0432.CCR-0740-3. View

20.

Ravacci G, Brentani M, Tortelli Jr T, Torrinhas R, Saldanha T, Torres E . Lipid raft disruption by docosahexaenoic acid induces apoptosis in transformed human mammary luminal epithelial cells harboring HER-2 overexpression. J Nutr Biochem. 2012; 24(3):505-15. DOI: 10.1016/j.jnutbio.2012.02.001. View